Assessment of proarrhythmic toxicity of newly developed drugs attracts significant attention
from drug developers and regulatory agencies. Although no guidelines exist for such …

The single most common cause of the withdrawal or restriction of the use of marketed drugs
has been QT-interval prolongation associated with polymorphic ventricular tachycardia, or …

Much attention recently has focused on drugs that prolong the QT interval, potentially
leading to fatal cardiac dysrhythmias (eg, torsade de pointes). We provide a detailed review …

There has been an increasing focus on drug induced QT prolongation including research on
drug development and QT prolongation, following the removal of drugs due to torsades de …

The prolonged QT interval is both widely seen and associated with the potentially deadly
rhythm, Torsades de Pointes (TdP). While it can occur spontaneously in the congenital form …

Assessing the potential for a new drug to cause life-threatening arrhythmias is now an
integral component of premarketing safety assessment. International Conference on …

Background and purpose: Drug‐induced prolongation of the QT interval can lead to torsade
de pointes, a life‐threatening ventricular arrhythmia. Finding appropriate assays from among …

Medicinal products that, as an unwanted effect, prolong the QT interval of the
electrocardiogram (ECG) can trigger episodes of polymorphic ventricular dysrhythmias …

The drug-induced QT prolongation predisposes to development of torsades de pointes
(TdP) ventricular tachycardia and sudden death. The association between specific drug and …

During the past decade, a number of non-cardiovascular drugs have had their label revised
or have been withdrawn from the market because of unexpected post-marketing reports of …